PDCD1 and renal cell adenocarcinoma: Furthermore, a programmed cell death-1 inhibitor such as pembrolizumab combined with a tyrosine kinase inhibitor such as axitinib may result in a better prognosis than sunitinib for previously untreated advanced RCC patients [61].